Navigation Links
Salix Pharmaceuticals Previews Digestive Disease Week 2007

es. In clinical trials, patients reported the following adverse events most frequently: headache (8%); abdominal pain (6%); diarrhea (5%); nausea (5%); vomiting (4%); respiratory infection (4%); and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to placebo.

XIFAXAN(R) (rifaximin) tablets 200 mg are indicated for the treatment of patients (greater than or equal to 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli. XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. In clinical trials, XIFAXAN was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %) and rectal tenesmus 7.2% (vs. 8.8%).

MOVIPREP(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities such as diuretics or angiotensin converting enzyme (ACE)-inhibitors or in patients with known or suspected hyponatremia. MOVIPREP should also be used with caution in patients with severe ulcerative colitis, ileus, gastrointestinal obstruction or perforation, gastric retention, toxic colitis, or toxic megacolon. In clinical trials, abdominal distension, anal discomfort, thirst, nausea and abdominal pain were some of the most common adverse reactions to MOVIPREP administration. Vomiting occurred less frequently.

Salix also markets OSMOPREP(TM) Tablets (sodium phosphate monobas
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Salix Pharmaceuticals Previews Digestive Disease Week
(Date:8/20/2014)... , August 20, 2014 Phase ... in the US  KalVista Pharmaceuticals ("KalVista"), an ... (DME), today announces that it has begun a Phase ... kallikrein inhibitor, KVD001, for the treatment of DME. The ... the Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical ...
(Date:8/19/2014)... , Aug. 19, 2014   Lincor ... its patient experience technology to New ... the five-year agreement, CarePoint Health will deploy Lincor,s ... Medical Center, Christ Hospital and Hoboken University Medical ... a range of software solutions to help hospitals ...
(Date:8/19/2014)... -- The Alabama Supreme Court, in a 6-3 decision on August ... mislead doctors into believing that prescription medicines the companies market ... Wyeth, and the decision came after the Supreme Court ruled ... Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a clear ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... 13 Octapharma USA ... therapy development specifically for von Willebrand Disease (VWD), is now ... Food and Drug Administration (FDA) has approved wilate® ... in patients with severe VWD as well as in patients ...
... May 13 Stereotaxis, (Nasdaq: STXS ... with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, ... the scientific program of the 31st Annual Heart Rhythm ... presentations and eight posters will underscore the broad clinical ...
Cached Medicine Technology:Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 2New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 3New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 5New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 6
(Date:8/20/2014)... No matter how “lonely” a person may be, he ... friends to be always there for them. However, it is ... making new friends during adulthood : not only is ... of one’s family to a near-slavish devotion to career-building, the ... just is not the same as it was when one ...
(Date:8/20/2014)... 20, 2014 Building on growing ... successfully predicted stage iii and iv pressure ulcers ... situations, approached 90%. A company spokesperson commented that ... commercial or academic settings. The resulting capabilities can ... of hospital-acquired conditions to help providers avoid financial ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 “Have you recently ... auto accident and personal injury lawyer serving the greater Seattle ... incident? If so, then keep reading . , In ... individuals injured in an auto accident can use to see ... explains that a personal injury insurance claim will allow an ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo ... prices. The well-known medium has been thrilling many with ... in 19 cities, with tickets becoming available August 15. ... visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, ... and San Diego. The medium’s fans can obtain Theresa ...
(Date:8/20/2014)... Wisconsin (PRWEB) August 20, 2014 BuyCheapTicketsToEvents.com ... and a wide selection of tickets to many events. Cheap ... that will begin in September. , Hockey fans are enthusiastic ... to obtain tickets for games. Now is the time to ... to begin in mere months. There will be a great ...
Breaking Medicine News(10 mins):Health News:‘How to Make Friends as an Adult by Just Being Yourself: Becoming a “People Person” In Three Steps or Less’ Gives Tips for Making Friends During Adulthood - Vinamy 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2
... pediatric research institution , ... Washington, DC (Vocus) November ... Research Institute , dedicated new research facilities today, increasing the space ... than 100,000 square feet. , , , , ,Elected officials and ...
... MedNotes offers personalized medication profiles, drug interaction and warning ... , NEW YORK, Nov. 24 ... medication and related health issues, today announced the launch ... way consumers can monitor and manage their own medications, ...
... For over a decade Ochsner Health System,has enjoyed a ... improved patient care, cost savings and increased revenues for,Ochsner,s ... New Orleans have,seen more than their share of tragedy. ... left the greater New Orleans hospital infrastructure,badly damaged. ...
... With the bWell-informed Health Plan Forecaster, Medicare shoppers can ... , NEW YORK, Nov. ... first day of the holiday shopping rush. For seniors ... options, there,s no better time to "shop" for coverage ...
... Nov. 24 In preparation for its January 1,2009 ... Francisco,s highly regarded Institute on Aging (IOA). , ... nonprofit, membership-based, "aging-in-place",program designed to help older adults and ... apartments, and neighborhoods as long as they wish or ...
... 75th Annual Stockholders Meeting of Florida’s Natural Growers ... on Monday, the 17th of November. The theme ... Value,” was appropriate since the Cooperative reported one ... despite an extremely challenging economic environment. In fact, ...
Cached Medicine News:Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 2Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 4Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 5Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:bWell-informed(TM) Adds Medicare Plan Tools for 2008 Open Enrollment Season 2Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 3
... Cruise Control is ... STAAR as a filter ... and aspiration tubing that ... the safety and efficiency ...
... The robust, compact Sleepscan Traveler provides the ... can acquire PSG data in the home, ... laboratory. Traveler sleep studies utilize the same ... in-lab studies. Sleepscan Traveler studies take full ...
... Pioneer in Digital EEG ,The company ... system presents the latest addition to ... VISION. This innovative system incorporates the ... and information management to offer you ...
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
Medicine Products: